Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.
Abstract
Pathways for presenting proteins from the extracellular fluids on MHC class I molecules have been described in macrophages. However, it is uncertain whether similar mechanisms exist in dendritic cells, because conventional preparations of these cells can be contaminated with macrophages. We addressed this issue by transducing granulocyte-macrophage CSF into bone marrow cultures followed by supertransfection with myc and raf oncogenes. These immortalized clones displayed dendritic morphology, and many expressed the dendritic cell-specific markers DEC-205 and 33D1 as well as high levels of MHC molecules and costimulatory molecules. Using these cloned dendritic cells, we found that exogenous OVA could be presented on both their MHC class I and class II molecules. This presentation was markedly enhanced when the Ag was particulate and internalized by phagocytosis. Presentation of particulate OVA on MHC class I molecules was insensitive to the weak base chloroquine, but was blocked by peptide aldehyde inhibitors of the proteasome, indicating that the class I-presented peptides were generated in the cytosol. Brefeldin A, which inhibits the exocytosis of newly synthesized proteins from the endoplasmic reticulum, also inhibited Ag presentation. These results establish that dendritic cells can present exogenous Ags on MHC class I molecules and appear to use a similar phagosome to cytosol pathway as macrophages. Therefore, dendritic cells are likely to play an important role in generating immune responses to tissue transplants and tumors in vivo. Furthermore, these findings provide an approach for targeting vaccine Ags into these cells to prime immune responses in vivo.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DC2.4 dendritic cell line exhibits features of dendritic cells including expression of dendritic cell-specific markers, cell morphology, and ability to phagocytose and present exogenous antigens on MHC class I and class II molecules.
“Here we used EVs derived from the DC2.4 dendritic cell line that has been well characterized and exhibits features of dendritic cells including the expression of dendritic cell-specific markers, cell morphology and has the ability to phagocytose and present exogenous antigens on both MHC class I and class II molecules (Shen et al., 1997).”
From Engineered Extracellular Vesicles Loaded With miR-124 Attenuate Cocaine-Mediated Activation of Microglia (2020) · cites this paper as Shen et al., 1997
Cited by
Sorted by citations
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243 · see citing works
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · see citing works
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006 · see citing works
Self-citationCross-Presentation, Dendritic Cells, Tolerance and Immunity
Heath, W. R., & Carbone, F. R. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.47 · Cited by 882 · see citing works
A Critical Role for Stat3 Signaling in Immune Tolerance
Cheng, F., Wang, H.-W., Cuenca, A., Huang, M., Ghansah, T., Brayer, J., Kerr, W. G., Takeda, K., Akira, S., Schoenberger, S. P., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00232-2 · Cited by 377 · see citing works
Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy
Demento, S. L., Eisenbarth, S. C., Foellmer, H. G., Platt, C., Caplan, M. J., Mark Saltzman, W., Mellman, I., Ledizet, M., Fikrig, E., Flavell, R. A., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.034 · Cited by 290 · see citing works
Kanchan, V., & Panda, A. K. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.08.015 · Cited by 283 · see citing works
Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system
Lhuillier, C., Rudqvist, N.-P., Elemento, O., Formenti, S. C., & Demaria, S. (2019) · Genome Medicine · doi:10.1186/s13073-019-0653-7 · Cited by 276 · see citing works
Ng, G., Sharma, K., Ward, S. M., Desrosiers, M. D., Stephens, L. A., Schoel, W. M., Li, T., Lowell, C. A., Ling, C.-C., Amrein, M. W., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.09.013 · Cited by 276 · see citing works
Kriegsman, B. A., Vangala, P., Chen, B. J., Meraner, P., Brass, A. L., Garber, M., & Rock, K. L. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900475 · Cited by 114 · see citing works
Self-citationCross-Presentation by Osteoclasts Induces FoxP3 in CD8+ T Cells
Kiesel, J. R., Buchwald, Z. S., & Aurora, R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803897 · Cited by 109 · see citing works
Okuma, A., Hanyu, A., Watanabe, S., & Hara, E. (2017) · Nature Communications · doi:10.1038/s41467-017-02281-x · Cited by 69 · see citing works
Chivero, E. T., Liao, K., Niu, F., Tripathi, A., Tian, C., Buch, S., & Hu, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00573 · Cited by 69 · see citing works
Kuchtey, J., Chefalo, P. J., Gray, R. C., Ramachandra, L., & Harding, C. V. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2244 · Cited by 66 · see citing works
Neutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine
Perche, F., Clemençon, R., Schulze, K., Ebensen, T., Guzmán, C. A., & Pichon, C. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.07.014 · Cited by 55 · see citing works
Medjmedj, A., Genon, H., Hezili, D., Loth, A. N., Clemençon, R., Guimpied, C., Mollet, L., Bigot, A., Wien, F., Hamacek, J., et al. (2025) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2025.102648 · Cited by 19 · see citing works
- Authors
- Shen, Z., Reznikoff, G., Dranoff, G., & Rock, K. L.
- Affiliations
- Division of Lymphocyte Biology, Dana Farber Cancer Institute, Harvard Medical School , Boston, MA 02115,
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-03
- Volume
- 158
- Issue
- 6
- Pages
- 2723-2730
- ISSN
- 1550-6606
- 0022-1767
- Cited by
- 702
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
